Metraipolis › archive › dc_53bc941b9f80

New Clinical Trials and Therapeutic Advances with Faricimab and Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration: A Durability-Oriented… — Europe PMC PMID:42072314

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42072314
DOI
10.3390/biomedicines14040773
License (as archived)
solo-consultazione
Archived
2026-11-03T17:36:55.093Z
SHA-256 of the archived text
bbd53106da377b649b6406f4215aa962237a2d4021925e6763c6ce562f314ea2
Stable URL of this page
https://metraipolis.com/documento/dc_53bc941b9f80

How to cite

New Clinical Trials and Therapeutic Advances with Faricimab and Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration: A Durability-Oriented… — Europe PMC PMID:42072314 — Europe PMC (en), https://europepmc.org/article/MED/42072314 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_53bc941b9f80 (Metraipolis archive dc_53bc941b9f80, sha256 bbd53106da377b649b6406f4215aa962237a2d4021925e6763c6ce562f314ea2)
BibTeX
@misc{dc53bc941b9f80,
  title = {New Clinical Trials and Therapeutic Advances with Faricimab and Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration: A Durability-Oriented… — Europe PMC PMID:42072314},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42072314},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_53bc941b9f80; sha256 bbd53106da377b649b6406f4215aa962237a2d4021925e6763c6ce562f314ea2},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42072314. Agents can read the archived copy with the MCP tool read_document.